The role of non-aromatizable testosterone metabolite in metabolic pathways

Physiological Research

Volumn 60, Issue 2, 2011, Pages 253-261

  Duskova M ^a   Pospisilova H ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Adipose tissue; Atherosclerosis; Metabolic syndrome; Non aromatizable androgen; Testosterone

Indexed keywords

EID: 79959202924     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932080     Document Type: Review

References (63)

1. AKERSTEDT T, PALMBLAD J, DE LA TORRE B, MARANA R, GILLBERG M: Adrenocortical and gonadal steroids during sleep deprivation. Sleep 3: 23-30, 1980.
2. AMORY JK, ANAWALT BD, MATSUMOTO AM, PAGE ST, BREMNER WJ, WANG C, SWERDLOFF RS, CLARK RV: The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 179: 2333-2338, 2008.
3. AUMUELLER G, EICHELER W, RENNEBERG H, ADERMANN K, VILJA P, FORSSMANN WG: Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues. Acta Anat 156: 241-252, 1996.
4. BÉLANGER C, HOULD FS, LEBEL S, BIRON S, BROCHU G, TCHERNOF A: Omental and subcutaneous adipose tissue steroid levels in obese men. Steroids 71: 674-682, 2006.
5. BLOUIN K, BOIVIN A, TCHERNOF A: Androgens and body fat distribution. J Steroid Biochem Mol Biol 108: 272-280, 2008.
6. BLOUIN K, RICHARD C, BROCHU G, HOULD FS, LEBEL S, MARCEAU S, BIRON S, LUU-THE V, TCHERNOF A: Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 191: 637-647, 2006.
7. BOLDUC C, LAROSE M, YOSHIOKA M, YE P, BELLEAU P, LABRIE C, MORISSETTE J, RAYMOND V, LABRIE F, ST-AMAND J: Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. J Mol Endocrinol 33: 429-444, 2004.
8. BOLDUC C, YOSHIOKA M, ST-AMAND J: Transcriptoric characterization of long term dihydrotestosterone effects in adipose tissue. Obesity 15: 1107-1132, 2007.
9. BRAMBILLA DJ, MATSUMOTO AM, ARAUJO AB, MCKINLAY JB: The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 94: 907-913, 2009.
10. BRUCHOVSKY N, WILSON JD: The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243: 2012-2021, 1968.
11. CHEN W, YANG CC, CHEN GY, WU MC, SHEU HM, TZAI TS: Patients with a large prostate show a higher prevalence of androgenetic alopecia. Arch Dermatol Res 296: 245-249, 2004.
12. DATI E, BARONCELLI GI, MORA S, RUSSO G, BALDINOTTI F, PARRINI D, ERBA P, SIMI P, BERTELLONI S: Body composition and metabolic profile in women with complete androgen insensitivity syndrome. Sex Dev 3: 188-193, 2009.
13. DENTI L, PASOLINI G, CORTELLINI P, SANFELICI L, BENEDETTI R, CECCHETTI A, FERRETTI S, BRUSCHIERI L, ABLONDI F, VALENTI G: Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH). Atherosclerosis 152: 159-166, 2000.
14. DOGRAMACI AC, BALCI DD, BALCI A, KARAZINCIR S, SAVAS N, TOPALOGLU C, YALCIN F: Is androgenetic alopecia a risk for atherosclerosis? J Eur Acad Dermatol Venereol 23: 673-677, 2009
15. DORFMAN RI, HAMILTON JB: Urinary excretion of androgenic substances after intramuscular and oral administration of testosterone propionate to humans. J Clin Invest 18: 67-71, 1939.
16. DUŠKOVÁ M, ČERMÁKOVÁ I, HILL M, VANKOVÁ M, ŠAMALÍKOVÁ P, STÁRKA L: What may be the markers of the male equivalent of polycystic ovary syndrome? Physiol Res 53: 287-294, 2004
17. DUŠKOVÁ M, HILL M, STÁRKA L: Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride. Endocr Regul 44: 3-8, 2010.
18. FELDMAN HA, LONGCOPE C, DERBY CA, JOHANNES CB, ARAUJO AB, COVIELLO AD, BREMNER WJ, MCKINLAY JB: Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87: 589-598, 2002.
19. FINASTERIDE MALE PATTERN HAIR LOSS STUDY GROUP: Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 12: 38-49, 2002.
20. FORD ES, FREEDMAN DS, BYERS T: Baldness and ischemic heart disease in a national sample of men. Amer J Epidemiol 143: 651-657, 1996.
21. GILLES GG, SEVERI G, SINCLAIR R, ENGLISH DR, MCCREDIE MR, JOHNSON W, BOYLE P, HOPPER JL: Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 11: 549, 2002.
22. GONZALEZ-GONZALEZ JG, MANCILLAS-ADAME LG, FERNANDEZ-REYES M, GOMEZ-FLORES M, LAVALLE-GONZALEZ FJ, OCAMPO-CANDIANI J, VILLARREAL-PEREZ JZ: Androgenetic alopecia and insulin resistance in young men. Clin Endocrinol 71: 494-499, 2009.
23. GONZÁLEZ-SANTOS MR, GAJÁ-RODRÍGUEZ OV, ALONSO-URIARTE R, SOJO-ARANDA I, CORTÉSGALLEGOS V: Sleep deprivation and adaptive hormonal responses of healthy men. Arch Androl 22: 203-207, 1989.
24. GORMLEY GJ, STONER E, RITTMASTER RS, GREGG H, THOMPSON DL, LASSETER KC, VLASSES PH, STEIN EA: Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 70: 136-141, 1990.
25. GRAY A, FELDMAN HA, MCKINLAY JB, LONGCOPE C: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73: 1016-1025, 1991.
26. GUPTA V, BHASIN S, GUO W, SINGH R, MIKI R, CHAUHAN P, CHOONG K, TCHKONIA T, LEBRASSEUR NK, FLANAGAN JN, HAMILTON JA, VIERECK JC, NARULA NS, KIRKLAND JL, JASUJA R: Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 296: 32-40, 2008.
27. HAWK W, BRESLOW RA, GRAUBARD BI: Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination survey. Cancer Epidemiol Biomerkers Prev 9: 523-527, 2000.
28. HAWKINS VN, FOSTER-SCHUBERT K, CHUBAK J, SORENSEN B, ULRICH CM, STANCYZK FZ, PLYMATE S, STANFORD J, WHITE E, POTTER JD, MCTIERNAN A: Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. Med Sci Sports Exerc 40: 223-233, 2008.
29. HERRERA CR, D'AGOSTINO RB, GERTSMAN BB, BOSCOO LA, BELANGER AJ: Baldness and coronary heart disease rates in men from the Farmingham Study. Am J Epidemiol 142: 828-833, 1995.
30. HIRSSO P, RAJALA U, HILTUNEN L, JOKELAINEN J, KEINÄNEN-KIUKAANNIEMI S, NÄYHÄ S: Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. Dermatology 214: 125-129, 2007.
31. HSIEH CC, THANOS A, MITROPOULOS D, DELIVELIOTIS C, MANTZOROS CS, TRICHOPOULOS D: Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 80: 699-703, 1999.
32. ILANGOVAN R, SITTADJODY S, BALAGANESH M, SIVAKUMAR R, RAVI SANKAR B, BALASUBRAMANIAN K, SRINIVASAN S, SUBRAMANIAN C, THOMPSON DM, QUEIMADO L, SRINIVASAN N: Dihydrotestosterone is a determinant of calcaneal bone mineral density in men. J Steroid Biochem Mol Biol 117: 132-138, 2009.
33. IMPERATO-MCGINLEY J, GUERRERO L, GAUTIER T, PETERSON RE: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186: 1213-1215, 1974.
34. KAUFMAN KD: Androgens and alopecia. Mol Cell Endocrinol 198: 89-95, 2002.
35. LESKO SM, ROSENBERG L, SHAPIRO S: A case-control study of baldness in relation to myocardial infarction in men. J Amer Med Assoc 269: 998-1003, 1993.
36. LI S, LI X, LI J, DENG X, LI Y, CONG Y: Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res 121: 127-134, 2007.
37. LITMAN HJ, BHASIN S, LINK CL, ARAUJO AB, MCKINLAY JB: Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 91: 4326-4334, 2006.
38. LOTUFO PA, CHAE CU, AJANI UA, HENNEKENS CH, MANSON JE: Male pattern baldness and coronary heart disease: the Physicians' Health Study. Arch Intern Med 160: 165-171, 2000.
39. MAIER U: Hormone profile in the aging male. Sien Med Wochenschr 151: 422-425, 2001.
40. MATILAINEN V, KOSKELA P, KEINANEN-KIUKAANNIEMI S: Early anderogenetic alopecia as a marker of insulin resistance. Lancet 356: 1165-1166, 2000.
41. MOVERARE-SKRTIC S, VENKEN K, ANDERSSON N, LINDBERG MK, SVENSSON J, SWANSON C, VANDERSCHUEREN D, OSCARSSON J, GUSTAFSSON JA, OHLSSON C: Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity 16: 662-672, 2006.
42. NG MK, QUINN CM, MCCROHON JA, NAKHLA S, JESSUP W, HANDELSMAN DJ, CELERMAJER DS, DEATH AK: Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol 42: 1306-1313, 2003.
43. NIELSEN TL, HAGEN C, WRAAE K, BRIXEN K, PETERSEN PH, HAUG E, LARSEN R, ANDERSEN M: Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 92: 2696-2705, 2007.
44. OH BR, KIM SJ, MOON JD, KIM HN, KWON YH, RYU SB, PARK YI: Association of benign prostatic hyperplasia with male pattern baldness. Urology 51: 744-748, 1998.
45. OPSTAD PK: The hypothalamo-pituitary regulation of androgen secretion in young men after prolonged physical stress combined with energy and sleep deprivation. Acta Endocrinol (Copenh) 127: 231-236, 1992.
46. ORWOLL ES, NIELSON CM, LABRIE F, BARRETT-CONNOR E, CAULEY JA, CUMMINGS SR, ENSRUD K, KARLSSON M, LAU E, LEUNG PC, LUNGGREN O, MELLSTRÖM D, PATRICK AL, STEFANICK ML, NAKAMURA K, YOSHIMURA N, ZMUDA J, VANDENPUT L, OHLSSON C; Osteoporotic Fractures in Men (MrOS) Research Group: Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab 95: E151-E160, 2010.
47. PIRKE KM, DOERR P: Age related changes in free plasma testosterone, dihydrotestosterone and oestradiol. Acta Endocrinol (Copenh) 80: 171-178, 1975.
48. POTTER LK, ZAGER MG, BARTON HA: Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats. Am J Physiol Endocrinol Metab 291: 952-964, 2006.
49. QIU Y, YANASE T, HU H, TANAKA T, NISHI Y, LIU M, SUEISHI K, SAWAMURA T, NAWATA H: Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology 151: 3307-3316, 2010.
50. SASMAZ S, SENOL M, OZCAN A, DOGAN G, TUNCER C, AKYOL O, SENER S: The risk of coronary heart disease in men with androgenetic alopecia. J Eur Acad Dermatol Venereol 12: 123-125, 1999.
51. SATO T, MATSUMOTO T, YAMADA T, WATANABE T, KAWANO H, KATO S: Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 300: 167-171, 2003.
52. SCATÀ MC, NAPOLITANO F, CASU S, CARTA A, DE MATTEIS G, SIGNORELLI F, ANNICCHIARICO G, CATILLO G, MOIOLI B: Ovine acyl CoA:diacylglycerol acyltransferase 1-molecular characterization, polymorphisms and association with milk traits. Anim Genet 40: 737-742, 2009.
53. SHAHAR E, HEISS G, ROSAMOND WD, SZKLO M: Baldness and myocardial infarction in men: the atherosclerosis risk in communities study. Am J Epidemiol 167: 676-683, 2008.
54. SIGNORELLI SS, BARRESI V, MUSSO N, ANZALDI M, CROCE E, FIORE V, CONDORELLI DF: Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease. J Endocrinol Invest 31: 1092-1097, 2008.
55. SINGH R, ARTAZA JN, TAYLOR WE, GONZALEZ-CADAVID NF, BHASIN S: Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptormediated pathway. Endocrinology 144: 5081-5088, 2003.
56. SOMJEN D, KOHEN F, GAYER B, KNOLL E, MANY A, STERN N: Dihydrotestosterone and estradiol-17beta mutually neutralize their inhibitory effects on human vascular smooth muscle cell growth in vitro. J Steroid Biochem Mol Biol 113: 171-176, 2009.
57. STÁRKA L, POSPÍSILOVÁ H, HILL M: Free testosterone and free dihydrotestosterone throughout the life span of men. J Steroid Biochem Mol Biol 116: 118-120, 2009.
58. STÁRKA L, DUSKOVÁ M, HILL M: Dihydrotestosterone and testosterone throughout the life span of Czech men. Neuro Endocrinol Lett 29: 201-204, 2008.
59. TREVISAN M, FARINARO E, KROGH V, JOSSA F, GIUMETTI D, FUSCO G, PANICO S, MELLONE C, FRASCATORE S, SCOTTONI A, et al.: Baldness and coronary heart disease risk factors. J Clin Epidemiol 46: 1213-1218, 1993.
60. UEMURA M, TAMURA K, CHUNG S, HONMA S, OKUYAMA A, NAKAMURA Y, NAKAGAWA H: Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99: 81-86, 2008.
61. VANDENPUT L, MELLSTROM D, LORENTZON M, SWANSON C, KARLSSON MK, BRANDBERG J, LONN L, ORWOLL E, SMITH U, LABRIE F, LJUNGGREN O, TIVESTEN A, OHLSSON C: Androgens and glucoronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 92: 4130-4137, 2007.
62. VAN DER MERWE J, BROOKS NE, MYBURGH KH: Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. Clin J Sport Med 19: 399-404, 2009.
63. YANES LL, ROMERO DG: Dihydrotestosterone stimulates aldosterone secretion by H295R human adrenocortical cells. Mol Cell Endocrinol 303: 50-56, 2009.